J&J's TAR-200 drug fails a phase 3 bladder cancer trial, but the company is still confident in the blockbuster potential of the programme.

Acclaimed program of ideas, in-depth analysis, and commentary on a variety of matters—political, economic, social, and cultural—important to progressive and radical thinking and activism. Against the ...